Equity Overview
Price & Market Data
Price: $12.05
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $312,180,544
Volume: 0
Performance Metrics
1 Week: 14.00%
1 Month: -24.31%
3 Months: -37.95%
6 Months: -46.56%
1 Year: -34.01%
YTD: -32.72%
Company Details
Employees: 38
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma. Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.